Get the app
US › Healthcare

BioAge Labs, Inc (BIOA)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$5.34-3.61%
Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue
$2.5M
Revenue YoY
+1.6%
Net profit
$-26.1M
EPS
$-0.58
EPS estimate
$-0.65
Net margin
-1,064.7%

EPS came in at -0.58 against a street estimate of -0.65 — a beat of 10.8%.

Key statistics

Market cap
$245.1M
Forward P/E
0.0
P/B
0.68
Book value
$7.54
EPS (TTM)
$-2.56
52-week high
$25.95
52-week low
$4.81
50-day MA
$7.08
200-day MA
$15.52
Beta
1.19

Analyst view

Analysts rate BioAge Labs, Inc a buy (7 buy, 3 hold, 0 sell out of 10) with an average price target of $32.56.

Shareholding

Insiders
2.36%
Institutions
91.28%

Largest institutional holders

FundStake
BlackRock Inc6.21%
Cormorant Asset Management, LLC5.21%
Sofinnova Ventures5.00%
Jupiter Topco LLC4.67%
Octagon Capital Advisors LP3.81%
RA Capital Management, LLC3.64%
MPM Oncology Impact Management LP3.63%
Vanguard Capital Management, LLC3.36%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for BioAge Labs, Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-11-07.